Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.42 |
| ▸ | TCF4 | P15884 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7549628 | 0.88 | CCR2 (0.71) | CCR2HTR1ADRD2HTR2AACHE | |
| SCHEMBL7549637 | 0.85 | CCR2 (0.62) | CCR2ACHECHEK2 | |
| SCHEMBL7553543 | 0.85 | CCR2 (0.79) | CCR2HTR1ADRD2HTR2AACHE | |
| SCHEMBL7550201 | 0.85 | CCR2 (0.67) | CCR2HTR1ADRD2HTR2AACHE | |
| SCHEMBL7554508 | 0.85 | CCR2 (0.72) | CCR2DRD2ACHEHRH3HDAC6 | |
| SCHEMBL7160131 | 0.84 | CCR2 (0.74) | CCR2ACHECHEK2TCF4CTNNB1 | |
| SCHEMBL7550045 | 0.83 | CCR2 (0.79) | CCR2HTR2AACHECHEK2 | |
| SCHEMBL7548595 | 0.83 | CCR2 (0.73) | CCR2ACHECHEK2TCF4CTNNB1 | |
| SCHEMBL7550203 | 0.83 | CCR2 (0.64) | CCR2HDAC6CHEK2 | |
| SCHEMBL7553813 | 0.82 | CCR2 (0.70) | CCR2ACHECHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | claimed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | claimed |
| EP-0927167-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1998006703-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | CCR2 2/4885HTR1A 3215/4885DRD2 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.